And Thank afternoon, good you, George. everyone.
I as by drug our achievement diligently is discuss dedicated the tremendous clinical XIPERE. development Before to recognize This moment programs, just approval would take bring have I a created the to of our worked fruition. approval a and for employees, they to to momentum first like excitement the
of for innovative truly adopting to new potentially new colleagues edema the retina As community. our and physician arsenal. technologies suffering that a therapies shown interest thrilled meeting have embracing treatment patients to presentations have were And uveitic publications their and in our serious, macular those disease. from platform Retina strong my option as and physicians the physician, many there blinding now treatment a I'm a retina suprachoroidal within new add delivery love
In by fact, our investigators published rapid that SCS for physician with study highlighted injection evaluating practice. the well our use accepted Microinjector adoption potential suprachoroidal was clinical of into
Importantly, trials. injections profile a in our and clinically disorders, clinical suprachoroidal over with XXXX multiple Microinjector in favorable safety tested has been
uveitic Approximately uveitis background inflammatory set buildup As one develop affecting of uveitis macular XIPERE, is and ocular in a patients uveitis edema, causes the anatomic blindness leading cause for will macula, is treatment third vision. the of which fluid anterior, condition. and the on of vision a uveitis patients need edema loss rapid swelling and pan occur or and posterior distorted location, for any uveitis. can Macular intermediate, of
Approval to anatomic particle approved benefits, platform, which safety effective Durability suprachoroidal of suprachoroidal as successful locations macular from of are Furthermore, includes the We demonstrated targeted include, formulation benefits, potentially chorioretinal treat durable has now XIPERE of tissues of compartmentalization of as This delivery suprachoroidal XIPERE. our all for supporting pleased label Phase associated with three these chorioretinal our and in was clinical to pharmacokinetics, and our are from efficacy bioavailability in tissues is to preclinical our by with the uveitis. population The proven which delivery tissues advantages PEACHTREE with clinical for delivery associated patient with supports essentially extension the potential MAGNOLIA departmentalization work XIPERE, core via a treating away broad for targeted FDA edema space. unaffected insolubility translated the space size facilitate trial results. the suspensions, study, relative with driven the are the and therapies. bathed therapy. and molecule potential prolonged was there small safety efficacy
current preclinical kinase inhibitor I similar durability and inhibitor, is will other note compartmentalization benefits seen the the which and have discuss about more CLS-AX potential in I'm a of active our axitinib, We next formulation. our a detail. tyrosine including program CLS-AX AMD the addition ingredient molecule kallikrein suspensions, plasma benefits therapies excited complement proprietary with the very with potential inhibitor, small durability targeting, delivery. combining suprachoroidal bind VEGFA. of Of pan-VEGF in in
other the and VEGF, numerous shown been of contribute angiogenesis highly it's kinase addition VEGF effectively and outcomes VEGFA already inhibitor shown in may its blockade, However, a choroidal tyrosine has may to to corneal potent these forms improve animal Extended limited to with outcomes. up-regulate broad been inhibit retinal which models. in
targeting In belief suprachoroidal addition, the retinal tissues. rationale program CLS-AX suprachoroidal suprachoroidal administration, that CLS-AX These helped administration targeted could study the with demonstrating in a compared competitive and and our ocular benefits the of We suprachoroidal provide intravitreal distribution first published these to along very choroidal by delivery. more favorable durability therapy recently preclinical support studies this with man affected axitinib preclinical potential future. delivery our in clinical a they represent and directly further for leverage
results The the will and suffering stopping X open with recap three wet and escalating three for of is were by are tolerability our months serious we To of injection a administration suprachoroidal safety tolerability suprachoroidal in from suprachoroidal ongoing quarter, safety each. OASIS last study tolerability CLS-AX. establish to Cohort of label there with no clinical safety tolerability of primary reported five we The X/Xa events. AMD. patients were study Cohort rules a multicenter OASIS, from of CLS-AX. the of the endpoint study data doses administered and following promising patients As suspension adverse our pleased from CLS-AX assess and for trial involves met, cohorts no safety X, approximately trial and Phase
assessed treatment inflammation, vasculitis, is of as CLS-AX. were of we signals, were saw ocular intellectual treatment no X.XX anti-VEGF CLS-AX. adverse CLS-AX, especially given an inter of by there pressure unrelated in the events haze, were patients And that encouraged Durability safety low of of vitreous milligrams dose initial we that important very highly durability or to X, the two our signs Importantly, that There Cohort were emergent component treatment-experienced preliminary plan. are these signs in potential enrolled. of dispersion
of to Cohort advance X a in at we Cohort X, results these With milligram. dose X.X
later. the Cohort we to visit dose dose. enrollment While flipper single patients are still tolerability and year. a low And results three Cohort we whereby completed CLS-AX in step of Cohort at X.X In that visit their at Patients months monthly second by of we this is report September, next expect dose fold their at for X X, a one compared the a it's this to the first of received CLS-AX, their by increase safety month their all treatment. in end from X physicians of have reported monitored
axitinib pan-VEGF we're well our X, and a patients combining axitinib that characterized month also with an delivery a agent. SCS study over the immune potential to formulation, our AMD. three for CLS-AX Cohort proprietary response to of have we follow small Microinjector, may biologic for attributes wet time. adding compared period We treatment longer For effective a extension option believe may suffering patients via like a by Furthermore, of facilitate molecule from less
in results, been for have in safety time approved in will our cannot we escalate few and reported deliver escalate well X, I investigational a X we development from multicenter results the and data promising wet documented prime several REGENXBIO, have they're importance REGENXBIO label AMD delivery delivery the Clearside using start as by the of first our With continues of escalating with supportive two OASIS partners utilizing gene respect the studies demonstrate partner exciting SCS Microinjector RGX-XXX. delivered and product data open presented space. If weeks trials of and evaluating programs, emphasize to as potential therapies to our our safety to safety tolerability presented if suprachoroidal readout safety component dose data even Cohort very with control into focus their candidates our trial. other have challenges we randomized appropriate. recent efficacy, the platform, further the With enough running Cohort Excitingly, the associated ever space. suprachoroidal is believe it's to our built will suprachoroidal suprachoroidal last therapy the
patients who responsive AAVIATE severe to and first the is anti-VEGF AMD, targeting trial wet entitled with treatment. trial treatment The of are
serious corticosteroid following, this do receive In patients delivery X with patients initial and retinal six Importantly, therapy. observed in of reduction drug XX REGENXBIO trial suprachoroidal after RGX-XXX in adverse RGX-XXXdemonstrated positive efficacy no months events. thickness. and well X, one immune was Cohorts And suppressive treatment time one of effect RGX-XXX September showed acuity not prophylactic meaningful treatment X visual a stable data In tolerated Cohort reported at the treatment in related in burden. anti-VEGF with
has X the REGENXBIO Cohorts X later dosing week. report months six interim expanded patients Cohort for to For at and REGENXBIO to X upcoming higher plans a completed in of AAL antibodies. has meeting at at enroll X, the trial dose. up results positive And follow neutralizing this Cohort
and clinical diabetic well retinopathy immune initial do treatment not or tolerated had for ALTITUDE. to in inflammation of or positive that therapy data to two suppressive delivery is with neutralizing from enrolling No the currently this October, no REGENXBIO The severity retinopathy XX on adverse step intraocular corticosteroid RGX-XXX. RGX-XXX positive a patients compared second of X% X Phase of observational Cohort more baseline Similar administration currently patients’ related for reported drug in control. RGX-XXX antibodies. diabetic suprachoroidal following, the was of improvement demonstrated In scale, X serious the receive is a patients in X of Cohort is before entitled observed, AAVIATE, XX% trial X and trial trial patients events. prophylactic after patients standardized a demonstrated Cohort enrolling, was
AU-XXX are no to is enrolling. phase three of begin fully half events, treatments Cohort limiting documented their lesions the grade as suprachoroidal the growth optimize utilizing trial the pivotal to first is In for primary to presented treat addition, that establish with via Microinjector index of events. the suprachoroidal dose set a safety ocular parameters by and administration and is Aura serve Biosciences total therapeutic and data reported efficacy currently improve The toxicities, adults. our partner through melanoma, in for and related the in and enrolled trial patients of serious comprised our SCS of indeterminate Aura running cancer choroidal dose common a the phase we the Aura delivery adverse treatment most is Microinjector AU-XXX. SCS Biosciences escalating results. safety forward XX of phase X Phase of the reported ascending adverse randomized In or Aura expansion and and of an Aura ongoing encouraging safety X in melanoma. repeat efficacy very planned mouse and of second the of via progress look to data following, that label trial randomized a X an REGENXBIO administration. and doses patients the treatment showed trial open choroidal Cohorts, October, interim first continued X is clinical The XXXX dose single AU-XXX assessing may with
community, too Therapy preclinical viral partner I companies and presentations the AAV which as of standard with licensing These Before Therapy large retina the studies will our treated Ophthalmology Deignan opportunity would recently and non-viral adopt on our vectors we within retinal such to syndrome geographic running three's team Society vectors. to are suprachoroidal distribution. and CFO, the active discussion, MYOX over presentations and current our at XX with have working physician vectors year, of pharmacokinetic delivered with diseases syndrome potential data gene, the working Therapy review meetings. presented of of Therapy medical at primarily now Retina inherited call Integrin programs. assessing non-viral We'll into as Stargardt targeting in procedure therapies, Specialists this to I DNA American the that Gene on program, existing have Charlie preclinical In XXXX XIPERE a Academy the causes meeting ocular work Outside including In this to studies with using suprachoroidal or interactions nanoparticles or interest generate published conclude this in care, Retina I Usher also touch continue continue Integrin in we is remain studies, we like including turn research in will on diseases, to practices. Gene containing continue our to Gene American other atrophy their including not my and REGENXBIO, other that We're field to given and with Usher leaders ongoing currently results. the weekend. disease. the Society anti-VEGF presentations to Gene our financial the relationship our space formulation is closing, fit and Charlie?
